Page last updated: 2024-12-08

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID196970
CHEMBL ID4297376
SCHEMBL ID1581157
MeSH IDM0443151

Synonyms (39)

Synonym
289483-69-8
e-7820
n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzenesulfonamide
e7820 ,
nsc719239
nsc-719239
n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide
3-cyano-n-(3-cyano-4-methyl-1h-indol-7-yl)benzenesulfonamide
benzenesulfonamide, 3-cyano-n-(3-cyano-4-methyl-1h-indol-7-yl)-
e 7820
tvh5k7949n ,
unii-tvh5k7949n
3-cyano-n-(3-cyano-4-methyl-1h-indole-7-yl)benzensulfonamide
er-68203-00
S6628
n-(3-cyano-4-methyl-1h -indol-7-yl)3-cyanobenzenesulfonamide
LWGUASZLXHYWIV-UHFFFAOYSA-N ,
SCHEMBL1581157
DTXSID20183142
CS-6075
HY-14571
F20780
DB12505
AKOS032944953
BCP25835
FT-0714239
BS-16799
o6m ,
3-cyano-n-(3-cyano-4-methyl-1h-indol-7-yl)benzene-1-sulfonamide
SB16542
EX-A1818
er68203-00
Q27290435
CHEMBL4297376
nsc777573
nsc-777573
EN300-7545157
AC-36189
Z3041516104

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" We investigated whether E7820 in combination with erlotinib, an EGFR-TKI, could overcome EGFR-TKI-resistance in the NSCLC cell lines A549 (KRAS; G12S), H1975 (EGFR; L858R/T790M), and H1650 (PTEN; loss, EGFR; exon 19 deletion), which are resistant to erlotinib."( Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"8-fold, RSE 13%) and increased relative bioavailability of E7820 by 36% (RSE 14%), although the effect on C (max) and AUC was not significant."( Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Beijnen, JH; Critchley, D; Huitema, AD; Jansen, M; Keizer, RJ; Schellens, JH; Wanders, J; Zamacona, MK, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" KP-1 tumor at a dosage close to that affording antitumor activity."( An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
Asada, M; Funahashi, Y; Ono, N; Semba, T; Sugi, NH; Wakabayashi, T; Yamamoto, Y; Yoshimatsu, K, 2004
)
0.32
"Patients received single daily doses of E7820 orally for 28 days in cycle 1, followed by a 7-day no-treatment period, after which time-uninterrupted daily dosing ensued."( Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Giles, FJ; Hook, L; Kelly, KR; Krivelevich, I; Mita, A; Mita, M; Okereke, C; Ricart, AD; Romero, O; Rossignol, DP; Rowinsky, EK; Takimoto, C; Tolcher, A, 2011
)
0.37
" Tumor growth inhibition was measured in mice bearing a pancreatic KP-1 tumor, dosed at 12."( Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
Beijnen, JH; Funahashi, Y; Huitema, AD; Keizer, RJ; Schellens, JH; Semba, T; Wanders, J, 2011
)
0.37
" Human daily dosing of 100 mg QD had previously been shown to be safe and tolerable."( A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
de Vos, F; Dean, E; Evans, TR; Flynn, M; Greystoke, A; Kristeleit, R; Lolkema, MP; Megui-Roelvink, M; Milojkovic Kerklaan, B; Ottesen, L; Plummer, R; Ranson, M; Reyderman, L; Schellens, JH; Slater, S; Witteveen, PO, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (27.78)29.6817
2010's7 (38.89)24.3611
2020's6 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.64 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (27.78%)5.53%
Reviews3 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (55.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]